AmgenAMGN
About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Employees: 26,700
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 170 | Existing positions closed: 140
1% more funds holding
Funds holding: 2,739 [Q2] → 2,769 (+30) [Q3]
3% more call options, than puts
Call options by funds: $2.62B | Put options by funds: $2.54B
2% less capital invested
Capital invested by funds: $134B [Q2] → $131B (-$2.84B) [Q3]
4% less repeat investments, than reductions
Existing positions increased: 1,077 | Existing positions reduced: 1,119
3.58% less ownership
Funds ownership: 79.49% [Q2] → 75.9% (-3.58%) [Q3]
21% less funds holding in top 10
Funds holding in top 10: 87 [Q2] → 69 (-18) [Q3]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 3%downside $256 | Underperform Reinstated | 10 Dec 2024 |
RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target | 25%upside $330 | Outperform Maintained | 27 Nov 2024 |
Citigroup Geoff Meacham 28% 1-year accuracy 7 / 25 met price target | 27%upside $335 | Neutral Initiated | 14 Nov 2024 |
Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target | 44%upside $380 | Buy Maintained | 12 Nov 2024 |
UBS Colin Bristow 13% 1-year accuracy 2 / 16 met price target | 24%upside $326 | Neutral Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 58 articles about AMGN published over the past 30 days
